2015 - Fellow of the Royal Society of New Zealand
Richard Beasley focuses on Asthma, Internal medicine, Pediatrics, Epidemiology and Allergy. His Asthma research is mostly focused on the topic Atopy. The Internal medicine study combines topics in areas such as Placebo and Anesthesia.
His studies deal with areas such as Wheeze, Body mass index, Obesity, Cross-sectional study and Asthma symptoms as well as Pediatrics. His Epidemiology study which covers Global health that intersects with Family medicine and Asthma mortality. His Allergy research is multidisciplinary, incorporating elements of Etiology and Environmental health.
Richard Beasley mainly investigates Asthma, Internal medicine, Anesthesia, Intensive care medicine and Randomized controlled trial. His study brings together the fields of Pediatrics and Asthma. Richard Beasley focuses mostly in the field of Pediatrics, narrowing it down to topics relating to Epidemiology and, in certain cases, Public health.
The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Surgery. His Anesthesia research incorporates themes from Crossover study, Metered-dose inhaler and Bronchodilator. His Randomized controlled trial study combines topics from a wide range of disciplines, such as Physical therapy and Clinical trial.
His main research concerns Asthma, Internal medicine, Randomized controlled trial, COPD and Intensive care medicine. His study on Budesonide is often connected to Periostin as part of broader study in Asthma. Richard Beasley combines subjects such as Gastroenterology and Placebo with his study of Internal medicine.
The study incorporates disciplines such as Regimen, Anesthesia, Mild asthma and Physical therapy in addition to Randomized controlled trial. His COPD research also works with subjects such as
Richard Beasley mostly deals with Asthma, Internal medicine, Randomized controlled trial, Periostin and COPD. In the subject of general Asthma, his work in Budesonide is often linked to Exhaled nitric oxide, thereby combining diverse domains of study. The various areas that he examines in his Internal medicine study include Gastroenterology and Inhalation.
His work carried out in the field of Randomized controlled trial brings together such families of science as Oxygen therapy, Placebo, Crossover study and Adverse effect. His Crossover study research is multidisciplinary, incorporating perspectives in Anesthesia and Stress ulcer. His study looks at the intersection of Allergy and topics like Environmental health with Cross-sectional study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The global burden of asthma: executive summary of the GINA Dissemination Committee Report
Matthew Masoli;Denise Fabian;Shaun Holt;Richard Beasley.
Allergy (2004)
International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods.
M. I. Asher;U. Keil;H. R. Anderson;R. Beasley.
European Respiratory Journal (1995)
Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC
Richard Beasley.
The Lancet (1998)
Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee.
R Beasley;N Pearce;E Von Mutius.
The Lancet (1998)
Cellular events in the bronchi in mild asthma and after bronchial provocation.
Richard Beasley;William R. Roche;J. Alan Roberts;Stephen T. Holgate.
The American review of respiratory disease (1989)
Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC)
Neil Pearce;Nadia Aït-Khaled;Richard Beasley;Javier Mallol.
Thorax (2007)
SUBEPITHELIAL FIBROSIS IN THE BRONCHI OF ASTHMATICS
WilliamR. Roche;JulieH. Williams;Richard Beasley;StephenT. Holgate.
The Lancet (1989)
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
M. Humbert;R. Beasley;J. Ayres;R. Slavin.
Allergy (2005)
Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood.
Hywel Williams;Colin Robertson;Alistair Stewart;Nadia Aït-Khaled.
The Journal of Allergy and Clinical Immunology (1999)
Epidemiology and costs of chronic obstructive pulmonary disease.
K R Chapman;D M Mannino;J B Soriano;P A Vermeire.
European Respiratory Journal (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Otago
University of London
University of Melbourne
Monash University
University of Oxford
University of Southampton
Southampton General Hospital
George Institute for Global Health
University of Ferrara
University of Barcelona
University of Rochester
Microsoft (United States)
University of Melbourne
National Institutes of Health
Eli Lilly (United States)
University of Arizona
Chinese Academy of Sciences
Donald Danforth Plant Science Center
Fred Hutchinson Cancer Research Center
University of Tokyo
Syngenta (Switzerland)
Washington State University
University of Michigan–Ann Arbor
University of British Columbia
McMaster University
University of Duisburg-Essen